Jaguar Health (JAGX) Stock Analysis & Winston Score

Jaguar Health is a small pharmaceutical company that makes medicines to treat digestive problems. Its main product is Mytesi (crofelemer), a prescription drug approved by the FDA to help adults with HIV/AIDS manage diarrhea caused by their antiretroviral medications. The drug is derived from the red sap of a South American tree called Croton lechleri, making it a plant-based prescription medicine — which is unusual in the pharmaceutical industry. Jaguar Health earns money by selling Mytesi to patients, mostly in the United States, through pharmacies and specialty distributors. The company is very small, with a market cap near zero, and it consistently spends far more than it earns, resulting in deep operating losses. Jaguar has been trying to expand Mytesi into other uses, such as treating diarrhea in cancer patients undergoing chemotherapy, but the key risk is whether it can generate enough revenue and secure additional financing to survive before running out of cash.